Plerixafor (AMD3100) 8HCl

別名：JM 3100 8HCl,Plerixafor Octahydrochloride,AMD3100 octahydrochloride,SID791 octahydrochloride

製品コード：S3013 純度：99.77%

Plerixafor (AMD3100, JM 3100,Plerixafor Octahydrochloride,AMD3100 octahydrochloride,SID791 octahydrochloride) 8HCl is the hydrochloride of Plerixafor, a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM in cell-free assays, respectively. Plerixafor can be used as an anti-HIV agent.

CAS No. 155148-31-5

サイズ	価格(税別)	在庫状況
5mg	JPY 22000	国内在庫あり
10mg	JPY 29500	国内在庫あり
50mg	JPY 40500	国内在庫あり
1g	JPY 295500	国内在庫なし(納期7~10日)

代表番号: 045-509-1970\|電子メール：[email protected] よく尋ねられる質問

文献中Selleckの製品使用例（45）

製品安全説明書

現在のバッチを見る：純度： 99.77%

99.77

Plerixafor (AMD3100) 8HCl関連製品

関連ターゲット	CXCR1 CXCR2 CXCR4 CXCR3	もっと見る
関連製品	SB225002 WZ811 Reparixin (Repertaxin) LIT-927 Navarixin (SCH-527123) UNBS5162 LY2510924 AZD5069 AMD3465 hexahydrobromide AMG 487 SX-682 Danirixin (GSK1325756) MSX-122	もっと見る
関連化合物ライブラリー	FDA-approved Drug Library Natural Product Library Bioactive Compound Library-I GPCR Compound Library	もっと見る

シグナル伝達経路

CXCRシグナル伝達経路

CXCR阻害剤の選択性比較

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	活性情報	PMID
human MT2 cells	Function assay	1 ug/mL	4 days	Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of viral p24 antigen production at 1 ug/mL after 4 days by ELISA	21168336
human MOLT4 cells	Function assay	1000 nM		Inhibition of Mab 12G5 binding to CXCR4 expressed in human MOLT4 cells at 1000 nM by FACS analysis	19451305
human U87 cells	Function assay	1000 nM		Antagonist activity at CXCR4 in human U87 cells assessed as inhibition of SDF1-induced modulation of cAMP production at 1000 nM by TR-FRET assay	17958344
human MT4 cells	Function assay		4 days	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus replication after 4 days by MTT assay, EC50=4 nM	20043638
HEK293 cells	Function assay		2 days	Antiviral activity against T20-resistant HIV1 NL4-3 infected in HEK293 cells assessed as inhibition of viral replication after 2 days, IC50=2.3 nM	19451305
U87	Function assay		15 mins	Antagonist activity at human CXCR4 expressed in human U87 cells expressing CD4 assessed as inhibition of CXCL12-induced cAMP production pretreated for 15 mins before forskolin challenge by TR-FRET analysis, IC50=0.695μM	21105715
MT4	Antiviral assay		5 days	Antiviral activity against HIV1 infected in MT4 cells expressing CXCR4 assessed as inhibition of virus-induced cytopathic effect after 5 days, EC50=0.002μM	22909088
CD44null	Function assay		7 days	Effect on human GBM2 cell differentiation assessed as increase in CD44null cells after 7 days by flow cytometric analysis	22909088
CD44null	Function assay		7 days	Effect on human GBM1 cell differentiation assessed as increase in CD44null cells after 7 days by flow cytometric analysis	22909088
CEM-SS cells	Function assay			Effective concentration of compound against HIV-1 LAI strain in CEM-SS cells, EC50=127 nM	14698189
rat IR983F cells	Function assay			Displacement of [125I]CXCL12 from CXCR4 in rat IR983F cells, IC50=108 nM	19053768
MT-4 cells	Function assay			Effective concentration of compound against HIV-1 IIIB strain in MT-4 cells, EC50=65 nM	14698189
human Jurkat cells	Function assay			Antagonist activity at CXCR4 in human Jurkat cells assessed as inhibition of SDF1-induced cell migration, IC50=27.4 nM	19188071
PBMC cells	Function assay			Effective concentration of compound against HIV-1 89.6 strain in PBMC cells, EC50=3.8 nM	14698189
GHOST CXCR4 cell line	Function assay			Inhibitory concentration of compound against HIV-1 LAI strain in GHOST CXCR4 cell line, IC50=0.95 nM	14698189
CHOK1 cells	Function assay			Displacement of [125I]SDF1alpha from CXCR4 expressed in CHOK1 cells, IC50=0.81 nM	17715128
human HL60 cells	Function assay			Displacement of [125I]SDF1alpha from CXCR4 in human HL60 cells, IC50=15.2 μM	19188071
MT4	Antiviral assay			Antiviral activity against HIV1 3B assessed as reduction in cytopathic effect in MT4 cells, EC50=0.011μM	17034122
MT4	Antiviral assay			Antiviral activity against X4-tropic HIV1 NL4.3 infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity, EC50=0.062μM	22579418
CHO	Function assay			Binding affinity to human recombinant CXCR4 expressed in CHO cells, Kb=0.077μM	22909088
CHO	Function assay			Antagonist activity at human recombinant CXCR4 expressed in CHO cells assessed as inhibition of SDF1a-induced electrical impedance by dielectric spectroscopic analysis, IC50=0.26μM	22909088
他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

生物活性

製品説明

Targets

CXCL12 ^[1] (Cell-free assay)	CXCR4 ^[1] (Cell-free assay)
5.7 nM	44 nM

In Vitro
In vitro	Plerixafor inhibits CXCL12-mediated chemotaxis with a potency lightly better than its affinity for CXCR4. ^[1] Plerixafor also antagonizes SDF-1/CXCL12 ligand binding with an IC50 of 651 nM. Plerixafor inhibits SDF-1 mediated GTP-binding, SDF-1 mediated calcium flux and SDF-1 stimulated chemotaxis with IC50 of 27 nM, 572 nM and 51 nM, respectively. Plerixafor does not inhibit calcium flux against cells expressing CXCR3, CCR1, CCR2b, CCR4, CCR5 or CCR7 when stimulated with their cognate ligands, nor does Plerixafor inhibit receptor binding of LTB4. Plerixafor does not, on its own, induce a calcium flux in the CCRF–CEM cells, which express multiple GPCRs including CXCR4, CCR4 and CCR7. ^[2]
実験結果図	Methods	Biomarkers	結果図	PMID
実験結果図	Immunofluorescence	CXCR4 β-arrestin2		28521261

In Vivo
In Vivo	A single topical application of Plerixafor promotes wound healing in diabetic mice by increasing cytokine production, mobilizing bone marrow EPCs, and enhancing the activity of fibroblasts and monocytes/macrophages, thereby increasing both angiogenesis and vasculogenesis. ^[3] Cohorts of mice are administered with PBS, IGF1, PDGF, SCF, or VEGF for five consecutive days and Plerixafor on the 5th day. The number and size of the colonies are highest in IGF1 plus Plerixafor injected mice compared to PDGF, SCF and VEGF treated groups, in combination with Plerixafor. ^[4]
動物実験	動物モデル	Twelve-week-old C57BL/6 mice with segmental bone defect
	投与量	5 mg/kg
	投与経路	Administered via i.p.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
臨床試験 (data from https://clinicaltrials.gov, updated on 2024-05-22)
NCT05421416	Not yet recruiting	Stem Cell Transplant Complications	AHS Cancer Control Alberta	April 1 2024	Phase 2
NCT05343572	Recruiting	Asherman Syndrome\|Atrophic Endometrium\|Recurrent Implantation Failure	Hugh Taylor\|Yale University	November 1 2023	Early Phase 1
NCT05844527	Recruiting	Wound of Skin\|Abdominal Wound	MedRegen LLC	November 20 2023	Phase 2
NCT05411575	Withdrawn	COVID-19 Acute Respiratory Distress Syndrome\|COVID-19	4Living Biotech\|4P-Pharma	July 19 2022	Phase 2
NCT05445128	Terminated	Sickle Cell Disease	Ensoma\|bluebird bio	June 24 2022	Phase 2
NCT05835726	Recruiting	Multiple Myeloma\|Daratumumab\|Autologous Stem Cell Transplantation\|Leukapheresis	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	January 1 2022	--

参考
[1] Zabel BA, et al. J Immunol. 2009, 183(5), 3204-3211. [2] Fricker SP, et al. Biochem Pharmacol. 2006, 72(5), 588-596. [3] Nishimura Y, et al. J Invest Dermatol. 2012, 132(3 Pt 1), 711-720. [4] Kumar S, et al. Bone, 2012, 50(4), 1012-1018. + 展開

参考

[4] Kumar S, et al. Bone, 2012, 50(4), 1012-1018.

+ 展開

化学情報

分子量	794.47	化学式	C₂₈H₅₄N₈.8HCl
CAS No.	155148-31-5	SDF	Download Plerixafor (AMD3100) 8HCl SDFをダウンロードする
Smiles	C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3.Cl.Cl.Cl.Cl.Cl.Cl.Cl.Cl
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	1年-80°Cin solvent
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	1个月-20°Cin solvent

In vitro
Batch:

Water : 100 mg/mL

DMSO : Insoluble ( 吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

Ethanol : Insoluble

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

希釈計算器分子量計算器

投与溶液組成計算機(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量 mg/kg 動物平均体重 g 投与体積（動物毎）μL 動物数匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

計算結果：

投与溶媒濃度： mg/ml;

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL, 注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法：Take μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

投与溶媒調製方法：μL DMSOストック溶液に μL Corn oil，を加え、完全溶解。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):